Skip to main content

Table 1 Patient characteristics

From: Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients

 All patients
(N = 186)
Cases
TIPN Gr 2–3
(N = 108)
Control
TIPN Gr 0–1
(N = 78)
Cancer Type
 Breast ca. a1356768
 Ovarian ca. a514110
Age (year)
median (range)
52 (25–81)56 (25–81)48 (27–73)
Chemotherapy regimenb
 AC or CEF f/b wPTX126 (68%)67 (62%)59 (77%)
 AC or CEF f/b DTX5 (3%)05 (6%)
 CPA + DTX4 (2%)04 (5%)
 Dose dense TC39 (21%)34 (32%)5 (6%)
 Tri TC12 (6%)7 (6%)5 (6%)
Maximum grade of TIPNc
 02 (1%)0 (0%)2 (3%)
 176 (41%)0 (0%)76 (97%)
 291 (49%)91 (84%)0 (0%)
 317 (9%)17 (16%)0 (0%)
Cumulative taxane dose (mg/m2)
median (range)
 PTX960 (560–1440)
(N = 177)
960 (560–1440)
(N = 108)
960 (688–1440) (N = 69)
 DTX300 (270–400)
(N = 9)
300 (270–400)
(N = 9)
Time to develop TIPN (days)
median (range)
33 (7–79)28 (7–79)35 (7–77)
Duration of TIPN (days)
median (range)
446 (0–1416)455 (70–1395)416 (0–1327)
Grade of TIPN at 1 year after taxane
 044 (24%)10 (9%)34 (44%)
 174 (40%)38 (35%)36 (46%)
 241 (22%)41 (38%)0 (0%)
 32 (1%)2 (2%)0 (0%)
 unknown25 (13%)17 (16%)8 (10%)
Full dose administration of taxane132 (71%)63 (58%)69 (88%)
Dose reduction or termination of taxane due to TIPN38 (20%)35 (32%)3 (4%)
Dose reduction or termination due to other reasons16 (8%)10 (9%)6 (7%)
SCN9A rs7607967
 GG24 (13%)15 (14%)9 (11%)
 GA84 (45%)43 (40%)41 (53%)
 AA78 (42%)50 (46%)28 (36%)
SCN9A rs12994338
 TT13 (7%)9 (8%)4 (5%)
 TC80 (43%)46 (43%)34 (44%)
 CC93 (50%)53 (49%)40 (51%)
SCN9A rs13017637
 TT3 (2%)1 (1%)2 (3%)
 TC37 (20%)16 (15%)21 (27%)
 CC146 (78%)91 (84%)55 (70%)
SCN10A rs12632942
 GG44 (24%)28 (26%)16 (20%)
 GA87 (47%)49 (45%)38 (49%)
 AA55 (29%)31 (29%)24 (31%)
SCN10A rs6795970
 AA4 (2%)3 (3%)1 (1%)
 AG47 (25%)25 (23%)22 (28%)
 GG135 (73%)80 (74%)55 (71%)
  1. aCa. cancer, bAC cyclophosphamide (600 mg/m2) and doxorubicin (60 mg/m2), CEF cyclophosphamide (500 mg/m2) with epirubicin (100 mg/m2) and 5-fluorouracil (500 mg/m2), f/b followed by, PTX paclitaxel, DTX docetaxel, CPA + DTX four cycles of cyclophosphamide (600 mg/m2, day 1) and docetaxel (75 mg/m2, day 1) every 3 weeks, dose dense TC paclitaxel (80 mg/m2, day 1, 8, 15) and carboplatin (AUC6, day 1) every 3 weeks, Tri TC six cycles of paclitaxel (175 mg/m2) and carboplatin (AUC6, day 1) every 3 weeks, cTIPN taxane-induced peripheral neuropathy
  2. SCN9A rs7607067, SCN9A rs12994338, SCN9A rs13017637, SCN10A rs12632942, and SCN10A rs6795970 represent polymorphisms